Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders

Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolut... Biopharmaceuticals, Venture Capital Hemab Therapeutics, Glanzmann Thrombasthenia, von Willebrand Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news